INOVIO PHARMACEUTICALS, INC. Cash and Restricted Cash
INOVIO PHARMACEUTICALS, INC. (INO) had Cash and Restricted Cash of $31.53 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31.53M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $26.27M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44.27M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.57M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $31.53M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $26.27M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $44.27M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $36.57M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $24.35M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $39.92M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $65.81M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $21.69M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $34.39M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $19.60M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $14.31M 10-K · filed 2026-03-12 |
| 2023-09-30 | $18.80M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $52.71M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $28.24M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $46.33M 10-K · filed 2025-03-18 |
| 2022-09-30 | $21.99M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $41.10M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $59.01M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $71.14M 10-K · filed 2024-03-06 |
| 2021-09-30 | $67.94M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $58.93M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $83.63M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $250.73M 10-K · filed 2024-03-06 |
| 2020-09-30 | $178.70M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $215.43M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $158.45M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $22.20M 10-K · filed 2023-03-01 |
| 2019-09-30 | $15.85M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $19.74M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $20.78M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $23.69M 10-K · filed 2022-03-01 |
| 2018-09-30 | $19.40M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $15.09M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $37.51M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $23.79M 10-K · filed 2021-03-01 |
| 2016-12-31 | $19.14M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |